Document is current

Any future updates will be listed below

1492 Telomere-targeting agent THIO in sequence with cemiplimab demonstrates long-term therapeutic benefits beyond treatment cessation – A phase 2 THIO-101 trial in advanced ICI resistant NSCLC patients

Crossref DOI link: https://doi.org/10.1136/jitc-2024-SITC2024.1492

Published Online: 2024-11-05

Published Print: 2024-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark